Date: 2012-10-12
Type of information: R&D agreement
Compound: DNA-based therapeutic vaccine
Company: Genetic Immunity (USA - Hungary) The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) (Germany)
Therapeutic area: Infectious diseases - Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease: Human Papilloma Virus (HPV) infection
Details: Genetic Immunity, a leader in immunotherapy technology product development, and DKFZ (German Cancer Research Center, Heidelberg, Germany) have signed a collaborative agreement to develop a DNA-based vaccine for the treatment of Human Papilloma Virus (HPV) infection that causes cervical cancer and other cancers of the anus, penis, vulva, vagina, and oropharynx. Present HPV vaccines (Cervarix®, Gardasil®) have no therapeutic effect on HPV-related diseases, so they will not treat existing diseases or conditions caused by HPV. The Division of Genome Modifications and Carcinogenesis led by Prof. Dr. Lutz Gissmann will initiate a preclinical research program to evaluate the therapeutic efficacy of the DKFZ\'s HPV-specific plasmid DNA using Genetic Immunity\'s nanomedicine formulation and Langerhans cell-targeting administration technologies.
Genetic Immunity has successfully tested in clinical trials DermaVir, a candidate immunotherapy for the cure of HIV. This new collaboration is using the clinically proven technology expanding the pipeline to another deadly viral disease that causes cancer. The partners will test whether HPV-specific memory T cells induced by Genetic Immunity\'s nanomedicine products could protect against cancer after infection has occurred.
Financial terms:
Latest news:
